Endo USA, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$3.2M
Doctors Paid
4,936
Transactions
10,790
2024 Total
$3.2M
Payment Breakdown by Category
Research$1.7M (53.6%)
Consulting$319,792 (9.9%)
Food & Beverage$286,823 (8.8%)
Travel$77,684 (2.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.7M | 42 | 53.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $421,635 | 127 | 13.0% |
| Grant | $383,810 | 9 | 11.8% |
| Consulting Fee | $319,792 | 72 | 9.9% |
| Food and Beverage | $286,823 | 10,237 | 8.8% |
| Travel and Lodging | $77,684 | 295 | 2.4% |
| Space rental or facility fees (teaching hospital only) | $15,375 | 7 | 0.5% |
| Education | $62.00 | 1 | 0.0% |
Payments by Type
Research
$1.7M
42 transactions
General
$1.5M
10,748 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Efficacy of a Step-wise Protocol in Optimizing CCH Outcomes in Men with Peyronies Disease | $1.4M | 0 | 2 |
| Improving Patient-Important Outcomes with Testosterone Replacement in Hypogonadal Men with a Prior History of Cancer | $141,389 | 0 | 1 |
| A NONINTERVENTIONAL, RETROSPECTIVE MULTICENTER STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF XIAFLEX IN ADULT MALE PARTICIPANTS WITH VENTRAL CURVATURE OF THE PENIS DUE TO PEYRONIES DISEASE. (RETRO-VC) | $87,372 | 1 | 19 |
| Efficacy of a novel collagenase clostridium histolyticum protocol for PD among prior non-responders: a randomized, controlled, single-blinded study | $25,347 | 0 | 1 |
| CLOSTRIDIUM HISTOLYTICUM COLLAGENASE INJECTION TREATMENT FOR URETHRAL DISEASE: A PROSPECTIVE, SINGLE CENTER, OPEN LABEL STUDY | $19,960 | 0 | 3 |
| CLINICAL EFFECTIVENESS OF SPLINTING AFTER COLLAGENASE CLOSTRIDIUM HISTOLYTICUM INJECTION FOR DUPUYTREN CONTRACTURE | $15,750 | 0 | 1 |
| AN OPEN-LABEL, RANDOMIZED, PARALLEL-GROUP, THREE TREATMENT ARM, MULTICENTER STUDY ON HYPOGONADAL MALES TO EVALUATE THE EFFECT ON 24-HOUR AMBULATORY BLOOD PRESSURE AFTER 16-WEEK CONTINUOUS TREATMENT WITH MARKETED TESTOSTERONE PRODUCTS | $10,554 | 0 | 6 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL TRIAL OF STRUCTURED OPIOID DISCONTINUATION VERSUS CONTINUED OPIOID THERAPY IN SUBOPTIMAL AND OPTIMAL RESPONDERS TO HIGH-DOSE LONG-TERM OPIOID ANALGESIC THERAPY FOR CHRONIC PAIN | $10,200 | 0 | 6 |
| A NONINTERVENTIONAL, RETROSPECTIVE MULTICENTER STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF XIAFLEX IN ADULT MALE PARTICIPANTS WITH VENTRAL CURVATURE OF THE PENIS DUE TO PEYRONIE'S DISEASE. (RETRO-VC) | $1,725 | 0 | 2 |
| 1B: Study #3033-2; Incidence and Predictors of Opioid Overdose and Death among ER/LA Opioid Analgesics Users as Measured by Diagnoses and Death Records A Retrospective Database Study | $442.50 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 198
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Svetlana Sabel, M.d, M.D | Pediatrics | West Orange, NJ | $13.10 | $0 |
| Dr. Dennis Brenner, M.d, M.D | Pediatric Endocrinology | West Orange, NJ | $13.10 | $0 |
| Dr. Elsie Foglio, D.o, D.O | Pediatric Gastroenterology | Newark, NJ | $13.10 | $0 |
| Coleman Mcferrin, Md, MD | Urology | Olathe, KS | $13.09 | $0 |
| Stephen Kwasniewski, Pa, PA | Physician Assistant | Hamilton, NJ | $13.09 | $0 |
| Bobbi Honkomp, Arnp, ARNP | Nurse Practitioner | Spencer, IA | $13.08 | $0 |
| David Christ, M.d, M.D | Specialist | Spencer, IA | $13.08 | $0 |
| George Gluck, M.d, M.D | Hand Surgery | Las Vegas, NV | $13.07 | $0 |
| Christopher Tam, Md, MD | Urology | Reno, NV | $13.07 | $0 |
| Penelope Pauley, Md, MD | Pediatric Endocrinology | Orlando, FL | $13.07 | $0 |
| Roland Goode, Md, MD | Urology | Reno, NV | $13.07 | $0 |
Ad
Top Products
- XIAFLEX $2.8M
- AVEED $189,843
Payment Categories
- Food & Beverage $286,823
- Consulting $319,792
- Travel & Lodging $77,684
- Research $1.7M
About Endo USA, Inc.
Endo USA, Inc. has made $3.2M in payments to 4,936 healthcare providers, recorded across 10,790 transactions in the CMS Open Payments database. In 2024, the company paid $3.2M. The top product by payment volume is XIAFLEX ($2.8M).
Payments were distributed across 101 medical specialties. The top specialty by payment amount is Urology ($278,015 to 1,762 doctors).
Payment categories include: Food & Beverage ($286,823), Consulting ($319,792), Research ($1.7M), Travel & Lodging ($77,684).